Clonorchiasis Market is Expected to Grow at a CAGR over 4.20% from 2022 to 2030

Pune, India, 2022 /MRFR Press Release/- Market Research Future published a half-cooked research report on global clonorchiasis market.

Global Clonorchiasis Market Highlights

Clonorchiasis is an infectious disease caused by the Chinese liver fluke Clonorchis sinensis. Clonorchiasis is dominant in Asian countries and regions, including South Korea, China, Northern Vietnam, and far-eastern Russia. China has the largest population of infected people. In the acute phase, heavier infections can cause fever, chills, epigastric pain, tender hepatomegaly, mild jaundice, and eosinophilia occur. Chronic cholangitis in heavy infections, which may progress to atrophy of liver parenchyma, portal fibrosis, and cirrhosis. Increasing prevalence of clonorchiasis, changing lifestyle, poor diet, and increasing geriatric population have driven the growth of the market. 

The Clonorchiasis Market is projected to reach USD 430 Million by 2030 at 4.20% CAGR during the forecast period 2022-2030.

Moreover, increasing healthcare expenditure has fuelled the growth of the market. On the other hand, high cost of the treatment may slow the market growth.

Segmentation

The global clonorchiasis market is segmented on the basis of parasites, therapy, and end users.

On the basis of the parasites, the market is segmented into Clonorchis sinensis, Opisthorchis viverrini, Opisthorchis felineus, and others.

On the basis of the therapy, the market is segmented into diagnosis and treatment. The diagnosis is further segmented into microscopic examination, X-ray, serologic tests, and others. The treatment is sub-segmented into praziquantel, cesol, cisticid, biltricide, and others.

On the basis of end users, the market is segmented into hospital, clinics, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Clonorchiasis Market Research Report

Regional Analysis

The Americas dominate the global clonorchiasis market owing to a large geriatric population, strong government support for research & development, and high healthcare spending. According to the Centers for Disease Control and Prevention in 2014, over 14.8 million of the U.S. population had GI diseases. Increasing prevalence of GI diseases has boosted the market growth. Additionally, poor diet and increasing awareness has fuelled the growth of the market. 

Europe is the second leading market across the globe, which is followed by Asia Pacific. Asia Pacific is the fastest growing market for Clonorchiasis. Asia Pacific clonorchiasis market is majorly driven by India, China, and South Korea owing to a huge patient pool, and continuously developing healthcare sector have fuelled the growth of the market. China has the largest population of infected people with Clonorchis sinensis. In 2013, over 13 million people were infected in China.

The Middle East and Africa contribute the least in the growth of the global clonorchiasis market. However, the Middle East is dominating the market of this region. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East market. However, Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition. However, the growth of the African market is high due to the presence of opportunities for the development of the market.

Key Players

The key players for the global clonorchiasis market are Pfizer (U.S), Bayer AG (Germany), Provet (Switzerland), Virbac (India), Cipla (India), Novartis AG (Switzerland), CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), Arsanis, Inc. (Austria), Novabiotics (U.K.), GlaxoSmithKline plc. (U.K.), and Teva Pharmaceutical Industries Ltd (Taiwan).